8th Sep 2025 16:27
(Alliance News) - Hemogenyx Pharmaceuticals PLC on Monday said it has agreed a manufacturing partnership with US-based cell therapy contract development and manufacturing organisation Made Scientific.
The London-headquartered biopharmaceutical company focused on treatments for blood diseases said the CDMO would support its advancement of HG-CT-1, Hemogenyx's autologous chimeric antigen receptor T-cell therapy for the treatment of relapsed/refractory acute myeloid leukemia in adults.
Shares in Hemogenyx Pharmaceuticals jumped 16% to 882.53 pence in London on Monday afternoon. The stock has risen 62% over the past year.
Under the terms of the deal, Hemogenyx will utilise Made Scientific's expertise in CAR-T cell therapy technology transfer and manufacturing at its GMP facilities in Newark and Princeton, in the US state of New Jersey.
The partnership is expected to accelerate Hemogenyx's ongoing phase 1 clinical trial of HG-CT-1 in adult patients and to support the potential inclusion of further cohorts for pediatric relapsed/refractory acute myeloid leukaemia patients.
"Partnering with a trusted CDMO like Made Scientific is essential to the success of HG-CT-1, our lead CAR-T therapy. Made's expertise in cell therapy manufacturing will be instrumental in driving the continued progress of this potentially breakthrough therapy for patients with relapsed or refractory AML, fully in line with our identity as a life saving company," said Hemogenyx Chief Executive Officer & Co-Founder Vladislav Sandler.
The company has already made "significant progress" in its phase 1 trial, Hemogenyx added, with early clinical data "supporting growing confidence in both safety and potential efficacy".
By Emily Parsons, Alliance News reporter
Comments and questions to [email protected]
Copyright 2025 Alliance News Ltd. All Rights Reserved.
Related Shares:
Hemogenyx